Phuong Khanh Morrow - 10 Mar 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
10 Mar 2023
Net transactions value
$0
Form type
4
Filing time
14 Mar 2023, 17:44:07 UTC
Previous filing
12 Oct 2022
Next filing
25 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +44,620 $0.000000 44,620 10 Mar 2023 Common Shares 44,620 $43.22 Direct F1
transaction CRSP Restricted Stock Units Award $0 +22,000 $0.000000 22,000 10 Mar 2023 Common Shares 22,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on March 10, 2023 with respect to 44,620 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.